论文部分内容阅读
目的:观察奥亭止咳露联合布地奈德气雾剂治疗咳嗽变异性哮喘(CVA)的效果及安全性。方法:将CVA72例分为3组:奥亭+布地奈德组30例,布地奈德组21例,泼尼松组21例,分别给予相应的药物治疗28d,观察咳嗽消失时间和支气管激发试验结果,并以积分法统计有效率和显效率,同时观察药物不良反应。结果:治疗14d,3组总有效率分别为90.00%、90.48%和90.48%,无统计学差异(P>005);但奥亭+布地奈德组显效率60%明显优于布地奈德组14.29%,(P<0.01),与泼尼松组(61.90%)相当(P>0.05)。奥亭+布地奈德组平均止咳时间(5.9±1.9)d,也与泼尼松组(6.8±2.2)d相当(P>0.05),但明显优于布地奈德组(9.9±3.2)d(P<0.01)。奥亭+布地奈德组有1例(3.33%)和布地奈德组有1例(4.76%)分别发生口腔霉菌感染和声音嘶哑,而泼尼松组共有8例(38.09%)出现不良反应,明显大于前两组(P<0.01)。结论:奥亭联合布地奈德是治疗CVA快速有效安全的新方法。
Objective: To observe the efficacy and safety of Austrian Ting cough syrup combined with budesonide aerosol in the treatment of cough variant asthma (CVA). Methods: 72 cases of CVA were divided into 3 groups: 30 patients in the Aoting + Budesonide group, 21 in the budesonide group and 21 in the prednisone group. The corresponding medication was given for 28 days. The duration of cough disappearance and the bronchial provocation test Results, and statistics by the integral method efficiency and markedly effective, while observing adverse drug reactions. Results: After 14 days of treatment, the total effective rates of the three groups were 90.00%, 90.48% and 90.48% respectively, with no significant difference (P> 005). However, the effective rate of 60% in the Aoting + Budesonide group was significantly better than that in the budesonide group 14.29% (P <0.01), which was equivalent to prednisone (61.90%) (P> 0.05). The average duration of cough relieving time was (5.9 ± 1.9) days in arotinib + budesonide group (6.8 ± 2.2 d vs prednisone group, P <0.05), but significantly better than that in budesonide group (9.9 ± 3.2 days) (P <0.01). One case (3.33%) in the Aoting + budesonide group and one case (4.76%) in the budesonide group had oral mold infection and hoarseness respectively, while 8 cases (38.09%) in the prednisone group had adverse reactions , Significantly higher than the first two groups (P <0.01). Conclusion: Aoting combined with budesonide is a new method for the rapid and effective treatment of CVA.